Join Trial Studying Weight Loss Drug for Type 2 Diabetes

Why is this study important?

This study will evaluate the effects of different doses of MariTide, an experimental once monthly injectable medication, in people with type 2 diabetes. Early results from another MariTide study presented in November 2024 showed up to 20% weight loss in individuals with obesity or overweight.

MariTide (maridebart cafraglutide) is different from other weight loss medications like tirzepatide (Zepbound) as it activates GLP-1 receptors while blocking GIP activity. If successful, this trial could provide valuable insights into the mechanism behind GLP-1 drugs and offer another potential option for managing blood sugar while supporting weight loss. 

How does the trial work?

Participants will be randomly assigned to either the active treatment or placebo group. Those assigned to the treatment group will receive MariTide at varying doses for up to 24 weeks. Both the treatment and placebo groups will have the option to continue to part two of the trial and receive MariTide for an additional 24 weeks if they complete the initial phase and meet certain eligibility requirements.

To determine the effectiveness of MariTide, researchers will measure participants’ AIC levels at the beginning of the study and at 24 weeks. They will also look at how MariTide affects body weight, fasting glucose, cholesterol, blood pressure, and other health measures to assess its safety and efficacy.

Are you interested in participating?

You may be eligible to participate if you are 18 years of age or older and have:

• Type 2 diabetes for more than six months (treated with either diet and exercise alone, or with a stable dose of metformin with or without an SGLT-2 inhibitor like Farxiga or Jardience for at least three months prior to screening)
• A1C of 7.0% to 10.5%
• BMI of 23-50 

People with type 1 diabetes are not eligible for this study. This trial is currently recruiting in locations throughout the U.S., Greece, Hungary, Japan, South Korea, Poland, Puerto Rico, Spain, and Sweden. See a full list of inclusion/exclusion criteria here.

Learn more about diabetes and weight loss here:

• Tips for Weight Loss Medications When You Have Diabetes
• Zepbound Shows Greater Weight Loss Than Wegovy in Major Trial
• New Weight Loss Drug CagriSema Shows Impressive Results in Clinical Trials